^
    Back
    Association details:
    Biomarker:BRAF mutation
    Cancer:Melanoma
    Drug:ulixertinib (BVD-523) (ERK2 inhibitor, ERK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

    Excerpt:
    ...NRAS, HRAS, BRAF, MEK, and ERK mutations....
    Trial ID:
    NCT04566393
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

    Excerpt:
    ...- Group 1: Patients with BRAF mutated cancer, except those with colorectal or non-small cell lung cancers...
    Trial ID:
    NCT01781429
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Discov
    Title:

    First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

    Excerpt:
    Ulixertinib has an acceptable safety profile with favorable pharmacokinetics and has shown early evidence of clinical activity in NRAS- and BRAF V600- and non-V600-mutant solid-tumor malignancies….In 19 such patients with BRAF-mutant melanoma previously treated with a BRAF and/or MEK inhibitor, 3 (15%) achieved a PR, 6 had stable disease, and 10 had progressive disease as a best response.
    DOI:
    10.1158/2159-8290.CD-17-1119
    Trial ID:
    NCT01781429